Loading...
Treating women with severe pregnancy hypertension and preeclampsia lowers risk for maternal and infant morbidity and mortality. However, optimal management of nonsevere pregnancy hypertension (i.e., blood pressure [BP] between 140/90 mm Hg and 159/109 mm Hg) is unclear, with limited evidence on the balance of maternal benefits versus fetal risks from pharmacotherapy. Researchers conducted a network meta-analysis of 61 trials that involved 7000 women with nonsevere pregnancy hypertension who were randomized to receive labetalol, methyldopa, calcium-channel blockers, other β-blockers, multiple-drug strategy, or placebo/no treatment. Outcomes of interest included severe hypertension (BP, ≥160/110 mm Hg), proteinuria/preeclampsia, fetal/newborn…